DA Versus DAC as Postoperative Adjuvant Treatment for Early-stage Breast Cancer
NCT02838225
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
300
Enrollment
OTHER
Sponsor class
Conditions
Breast Cancer
Interventions
DRUG:
Docetaxel, Doxorubicin
DRUG:
Docetaxel, Doxorubicin, Cyclophosphamide
Sponsor
Peking Union Medical College Hospital